Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Proteomic profile and in silico analysis in metastatic melanoma with and without BRAF mutation.

PloS one - 1 Jan 2014

Garrisi Vito Michele, Strippoli Sabino, De Summa Simona, Pinto Rosamaria, Perrone Antonella, Guida Gabriella, Azzariti Amalia, Guida Michele, Tommasi Stefania, Stefania Tommasi

Abstract excerpt

INTRODUCTION: Selective inhibitors of BRAF, vemurafenib and dabrafenib are the standard of care for metastatic melanoma patients with BRAF V600, while chemotherapy continued to be widely used in BRAF wild type patients. MATERIALS AND METHODS: In order to discover novel candidate biomarkers predictive to treatment, serum of 39 metastatic melanoma vemurafenib (n = 19) or chemotherapy (n = 20) treated patients at...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Computer Simulation
Share to Indoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Neoplasm Metastasis

Share to Proteomics

Share to Proto-Oncogene Proteins B-raf

Share to Sulfonamides

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 25437182
DOI: 10.1371/journal.pone.0112025
PMCID: PMC4249853

Genes

BRAF
ABCC12
KLF17
NQO1
RBM10
RIN1
SLAIN1
TOX3
TSPO2
ZBTB44

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Proteomic profile and in silico analysis in metastatic melanoma with and without BRAF mutation.PMID 25437182Read ↗

Clinical Proteomics of Metastatic Melanoma Reveals Profiles of Organ Specificity and Treatment Resistance.Semantic proximity Read ↗

The Hidden Story on Heterogeneous B-raf V600E Mutation Quantitative Protein Expression in Metastatic Melanoma – Association with Clinical Outcome and Tumor PhenotypesSemantic proximity Read ↗

Imaging Mass Spectrometry for the Classification of Melanoma Based on BRAF/NRAS Mutational Status.Semantic proximity Read ↗

The Human Melanoma Proteome Atlas-Complementing the melanoma transcriptome.Semantic proximity Read ↗

Histopathology-assisted proteogenomics provides foundations for stratification of melanoma metastasesSemantic proximity Read ↗

Proteogenomic Characterization Reveals Therapeutic Opportunities Related to Mitochondrial Function in MelanomaSemantic proximity Read ↗

Multi-omics analysis delineates resistance mechanisms associated with BRAF inhibition in melanoma cells.Semantic proximity Read ↗

Precision Medicine and Melanoma: Multi-Omics Approaches to Monitoring the Immunotherapy ResponseSemantic proximity Read ↗

Identification of biomarkers of metastatic disease in uveal melanoma using proteomic analysesSemantic proximity Read ↗

Tracking of Glycans Structure and Metallomics Profiles in BRAF Mutated Melanoma Cells Treated with Vemurafenib.Semantic proximity Read ↗

miR-410-3p is induced by vemurafenib via ER stress and contributes to resistance to BRAF inhibitor in melanomaSemantic proximity Read ↗

Deep Proteomic Analysis on Biobanked Paraffine-Archived Melanoma with Prognostic/Predictive Biomarker Read-OutSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.